\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes Horizon Europe Digital Europe Horizon 2020Cascade funding, also known as Financial Support to Third Parties (FSTP), is a mechanism of the European Commission to distribute public funds in order to assist startups, scale-ups, SMEs and/or mid-caps in the uptake or development of innovation.
FSTP is a SME-friendly application scheme which allows that some EU-funded projects may issue, in turn, open calls for further funding. Currently, only the Horizon and Digital programmes may foresee the use of this feature.
All registered cascade funding calls are now available on the Funding & Tenders Portal: Search Funding & Tenders (europa.eu)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Culture and society Security
In the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA): Simplified section 2.1 'Project's pathways towards impac... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
